



Number of shares comprising the share capital: 15,174,125

Number of shares with voting rights: 15,031,080

Number of shares with voting rights possessed by shareholders presents or represented or having voted by mail: 13,070,268

That means a quorum of 86.95% of the 15,031,080 shares with voting rights: <u>the Ordinary Annual General Meeting was able to deliberate</u>.

The Ordinary Annual General Meeting was held on Thursday, 27 June 2024 at 5:30 p.m. at the Company's headquarters and approved the separate parent company and consolidated financial statements for the 2023 financial year. The results of the votes on the resolutions proposed at this meeting by the Board of Directors were as follows:

Resolutions	Results of the votes
RESOLUTION ONE Approval of the annual financial statements	Resolution adopted by: - 13,068,136 votes in favour - 0 vote against - 2,132 abstentions
 RESOLUTION TWO Discharge of directors and discharge of the Statute Auditors for the performance of their engagement 	Resolution adopted by: - 12,777,518 votes in favour - 290,512 votes against - 2,238 abstentions
RESOLUTION THREE Approval of the consolidated financial statements	Resolution adopted by: - 13,068,136 votes in favour - 0 vote against - 2,132 abstentions
RESOLUTION FOUR Appropriation of earnings, setting the dividend	Resolution adopted by: - 13,070,236 votes in favour - 0 vote against - 32 abstentions
 RESOLUTION FIVE Agreements and commitments governed by Article 225-38 of the French Commercial Code 	Resolution adopted by (*): - 13,023,724 votes in favour - 46,492 votes against - 32 abstentions



 RESOLUTION SIX Renewal of Ms. Sophie MAYE Director 	EUX's term of office as	Resolution adopted by: - 10,650,758 votes in favour - 2,419,478 votes against - 32 abstentions
 RESOLUTION SEVEN Appointment of BM&A as Sus 	tainability Auditor	Resolution adopted by: - 13,070,236 votes in favour - 0 vote against - 32 abstentions
 RESOLUTION EIGHT Approval of the information or corporate officers paid in or grand mentioned in Article L. 22 Commercial Code 	ranted for fiscal 2023	Resolution adopted by: - 12,189,192 votes in favour - 881,044 votes against - 32 abstentions
 RESOLUTION NINE Approval of the components of 2023 to Mr. Thierry CHAPUSO Board of Directors 		Resolution adopted by: - 13,006,839 votes in favour - 63,397 votes against - 32 abstentions
 RESOLUTION TEN Approval of the components of 2023 to Mr. Dominique PAUT Officer until 22/04/2022 		Resolution adopted by: - 13,070,236 votes in favour - 0 vote against - 32 abstentions
 RESOLUTION ELEVEN Approval of the components of 2023 to Mr. Denis SUPPLISS Officer 		Resolution adopted by: - 10,519,109 votes in favour - 2,551,127 votes against - 32 abstentions
 RESOLUTION TWELVE Approval of the components of 2023 to Mr. Grégoire DE ROT 		Resolution adopted by: - 10,468,599 votes in favour - 2,601,637 votes against - 32 abstentions
 RESOLUTION THIRTEEN Approval of the compensation CHAPUSOT, Chairman of the 2024 		Resolution adopted by: - 13,006,839 votes in favour - 63,397 votes against - 32 abstentions
 RESOLUTION FOURTEEN Approval of the compensation SUPPLISSON, Chief Executive 		Resolution adopted by: - 10,473,009 votes in favour - 2,356,603 votes against - 240,656 abstentions
 RESOLUTION FIFTEEN Approval of the compensation de ROTALIER, Deputy Chief 2024 		Resolution adopted by: - 10,472,921 votes in favour - 2,356,691 votes against - 240,656 abstentions



•	RESOLUTION SIXTEEN Approval of the compensation policy for Mr. Damien VALICON, Deputy CEO (non-Board member), as from 01/04/2024	Resolution adopted by: - 10,462,222 votes in favour - 2,367,390 votes against - 240,656 abstentions
	RESOLUTION SEVENTEEN Approval of the compensation policy for Directors	Resolution adopted by: - 12,985,338 votes in favour - 63,397 votes against - 21,533 abstentions
•	RESOLUTION EIGHTEEN Setting total annual compensation for Directors for 2024	Resolution adopted by: - 12,985,338 votes in favour - 63,397 votes against - 21,533 abstentions
-	RESOLUTION NINETEEN Authorisation by the Company to repurchase its own shares	Resolution adopted by: - 10,931,253 votes in favour - 2,139,015 votes against - 0 abstention
•	RESOLUTION TWENTY Powers for formalities	Resolution adopted by: - 13,070,236 votes in favour - 0 vote against - 32 abstentions

^(*) After deduction of excluded voting rights

Financial Calendar:

- Publication of H1 2024 Revenue: 2 August 2024 (after French market closure).

About Group Equasens

With more than 1,300 employees, Equasens Group is today a key player in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, Hospital-at-Home structures, retirement homes, health centres) in both primary and secondary care sectors.

With operations in France, Germany, Great Britain, Belgium, Ireland, Italy, and Luxembourg, Equasens Group today brings together healthcare professionals within a unique ecosystem in France and Europe benefiting people by making available the very best of technology.



Listed on Euronext Paris™ - Compartment B

Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable Included in the Euronext Tech Leaders segment and the European Rising Tech label



Eligible for the Deferred Settlement Service ("Service à Règlement Différé" - SRD) and equity savings accounts invested in small and mid caps (PEA-PME)
ISIN: FR 0012882389 – Ticker Code: EQS

Get all the news about the Equasens Group www.equasens.com and on LinkedIn

CONTACTS

Analyst and Investor Relations:

Chief Administrative and Financial Officer: Frédérique SCHMIDT Tel. +33 (0)3 83 15 90 67 - frederique.schmidt@equasens.com

Media Relations:

FIN'EXTENSO - Isabelle APRILE

Tel. +33 (0)6 17 38 61 78 – <u>i.aprile@finextenso.fr</u>